Weather Gauge Advisory LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 8.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 41,730 shares of the biopharmaceutical company’s stock after selling 3,947 shares during the quarter. Pfizer accounts for 1.6% of Weather Gauge Advisory LLC’s portfolio, making the stock its 20th biggest holding. Weather Gauge Advisory LLC’s holdings in Pfizer were worth $1,365,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of PFE. New England Investment & Retirement Group Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at about $26,000. Lion Street Advisors LLC purchased a new position in shares of Pfizer in the first quarter worth approximately $27,000. Benjamin Edwards Inc. grew its position in Pfizer by 49.8% during the first quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 335 shares during the period. Disciplined Investments LLC increased its holdings in Pfizer by 43.3% during the first quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 347 shares during the last quarter. Finally, Efficient Wealth Management LLC bought a new position in Pfizer in the first quarter worth approximately $50,000. 70.20% of the stock is currently owned by institutional investors.
Shares of NYSE:PFE traded up $0.02 during midday trading on Tuesday, reaching $35.23. 30,968,878 shares of the company were exchanged, compared to its average volume of 30,354,449. The stock has a market cap of $195.59 billion, a PE ratio of 12.53, a price-to-earnings-growth ratio of 2.65 and a beta of 0.68. The business’s fifty day moving average is $34.65 and its two-hundred day moving average is $35.96. Pfizer Inc. has a one year low of $27.88 and a one year high of $43.23. The company has a current ratio of 1.02, a quick ratio of 0.78 and a debt-to-equity ratio of 0.56.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 31st will be paid a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 4.31%. The ex-dividend date of this dividend is Thursday, July 30th. Pfizer’s payout ratio is presently 51.53%.
In other Pfizer news, EVP Douglas M. Lankler sold 65,000 shares of the stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the completion of the transaction, the executive vice president now owns 135,375 shares in the company, valued at $5,123,943.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction on Friday, June 5th. The stock was sold at an average price of $36.13, for a total transaction of $78,799.53. Following the completion of the transaction, the senior vice president now directly owns 7,542 shares of the company’s stock, valued at $272,492.46. The disclosure for this sale can be found here. Insiders have sold a total of 69,362 shares of company stock valued at $2,622,691 in the last 90 days. 0.08% of the stock is currently owned by company insiders.
PFE has been the subject of several analyst reports. Mizuho initiated coverage on Pfizer in a research note on Monday, June 29th. They issued a “buy” rating and a $38.00 price objective for the company. TheStreet raised Pfizer from a “c+” rating to a “b” rating in a research note on Monday, June 1st. JPMorgan Chase & Co. cut their price objective on Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Monday, June 1st. Morgan Stanley decreased their target price on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 2nd. Finally, Barclays dropped their price target on shares of Pfizer from $37.00 to $35.00 in a research report on Monday, June 1st. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $38.72.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: What is dividend yield?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.